Social Links

Follow on Facebook Follow on Twitter Follow on G+Follow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Review article: Probiotics in gastrointestinal and liver diseases

 

 

 

Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:133-48.

 

Review article: Probiotics in gastrointestinal and liver diseases.

 

Jonkers D, Stockbrügger R. Div. Gastroenterology-Hepatology, University Hospital Maastricht, Maastricht, The Netherlands. This email address is being protected from spambots. You need JavaScript enabled to view it.

 

BACKGROUND: Probiotics, defined as live micro-organisms with beneficial effects for the host, are widely applied in gastrointestinal and liver diseases.

 

AIM AND METHOD: To review the available evidence of clinical trials on probiotics in gastrointestinal and liver diseases, with a major focus on irritable bowel syndrome, inflammatory bowel disease, pancreatitis and chronic liver diseases.

 

RESULTS: Evidence for the therapeutic or preventive application of particular probiotic strains is available for antibiotic-associated diarrhoea, rota-virus-associated diarrhoea and pouchitis. Results are encouraging for irritable bowel syndrome, ulcerative colitis and for reducing side effects by Helicobacter pylori eradication therapies, but are less clear for Crohn's disease, lactose intolerance and constipation. In general, for most of these patient groups, more placebo-controlled methodologically well-designed studies that pay attention to both clinical outcome and mechanistic aspects are required. The application in liver disease and pancreatitis is promising, but more human trials have to be awaited. Possible mechanisms of probiotics include modulation of the intestinal microbiota and the immune system, but different bacterial may have different effects.

 

CONCLUSION: Further insight into disease entities and the functioning of probiotic strains is required to be able to select disease-specific strains, which have to be tested in well-designed placebo-controlled studies.

 

PMID: 18081657 [PubMed - in process]

 


 

 

Related Articles:

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner